The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The potential for early identification of relapse in DLBCL using serial ctDNA sampling
Levels of plasma circulating tumor DNA (ctDNA) have been found to be prognostic in patients with diffuse large B-cell lymphoma (DLBCL). Nathalie Johnson, MD, PhD, Jewish General Hospital, Montreal, Canada, shares insights from a study that aimed to investigate the ctDNA dynamics in patients with DLBCL at different time points of the disease timeline. In serial samples, ctDNA levels decreased by cycle 2 of both frontline and salvage therapies, and this, along with measurable residual disease (MRD)-negativity at the end of treatment, is associated with favorable clinical outcomes. Dr Johnson suggests that using ctDNA and MRD could be a useful prognostic tool for predicting relapse in patients as levels rise over time following the achievement of a complete response (CR). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Gilead, Abbvie, Merck, Roche
Honoraria: Merck, Roche
